Literature DB >> 21877175

Streptococcus pyogenes bacteraemia, emm types and superantigen profiles.

S Rantala1, S Vähäkuopus, T Siljander, J Vuopio, H Huhtala, R Vuento, J Syrjänen.   

Abstract

The aim of this study was to investigate the emm types and superantigen profiles of bacteraemic group A streptococcal (GAS; Streptococcus pyogenes) isolates and to detect possible associations between the molecular characteristics of isolates and the clinical presentations of disease. In this population-based study, 87 bacteraemic GAS isolates from adult patients in Pirkanmaa Health District (HD), Finland, during the period 1995-2004 were emm typed and genotyped for superantigen (SAg) profiles. The epidemiological and clinical data of the patients were analysed with the microbiological characterisation data. Among the 87 isolates, 18 different emm types were found. emm1, emm28 and emm81 were the three most common types, covering 52% of isolates. The prevalence of specific emm types showed high variability during the 10-year study period. We could not find any association between the emm type and clinical features of bacteraemic infection, such as underlying diseases, disease manifestations or case fatality. Of nine superantigen genes examined, speA and speC were identified in 20 and 30% of the strains, respectively. No association was found between disease manifestation and the presence of single superantigen genes. The 26-valent GAS vaccine would have covered only 62% of isolates causing invasive disease in Pirkanmaa HD during the study period.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21877175     DOI: 10.1007/s10096-011-1385-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  37 in total

1.  Toxin-gene profile heterogeneity among endemic invasive European group A streptococcal isolates.

Authors:  Franz-Josef Schmitz; Andreas Beyer; Emmanuelle Charpentier; Birgitta Henriques Normark; Marc Schade; Ad C Fluit; Dieter Hafner; Rodger Novak
Journal:  J Infect Dis       Date:  2003-11-05       Impact factor: 5.226

2.  Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression.

Authors:  J M Musser; A R Hauser; M H Kim; P M Schlievert; K Nelson; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

Review 3.  Molecular basis of group A streptococcal virulence.

Authors:  A L Bisno; M O Brito; C M Collins
Journal:  Lancet Infect Dis       Date:  2003-04       Impact factor: 25.071

4.  Epidemic of severe Streptococcus pyogenes infections in injecting drug users in the UK, 2003-2004.

Authors:  T L Lamagni; S Neal; C Keshishian; V Hope; R George; G Duckworth; J Vuopio-Varkila; A Efstratiou
Journal:  Clin Microbiol Infect       Date:  2008-11       Impact factor: 8.067

5.  Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome.

Authors:  D F Talkington; B Schwartz; C M Black; J K Todd; J Elliott; R F Breiman; R R Facklam
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

6.  Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group.

Authors:  H D Davies; A McGeer; B Schwartz; K Green; D Cann; A E Simor; D E Low
Journal:  N Engl J Med       Date:  1996-08-22       Impact factor: 91.245

7.  Epidemiology of severe Streptococcus pyogenes disease in Europe.

Authors:  Theresa L Lamagni; Jessica Darenberg; Bogdan Luca-Harari; Tuula Siljander; Androulla Efstratiou; Birgitta Henriques-Normark; Jaana Vuopio-Varkila; Anne Bouvet; Roberta Creti; Kim Ekelund; Maria Koliou; Ralf René Reinert; Angeliki Stathi; Lenka Strakova; Vasilica Ungureanu; Claes Schalén; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

8.  Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe.

Authors:  Bogdan Luca-Harari; Jessica Darenberg; Shona Neal; Tuula Siljander; Lenka Strakova; Asha Tanna; Roberta Creti; Kim Ekelund; Maria Koliou; Panayotis T Tassios; Mark van der Linden; Monica Straut; Jaana Vuopio-Varkila; Anne Bouvet; Androulla Efstratiou; Claes Schalén; Birgitta Henriques-Normark; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2009-01-21       Impact factor: 5.948

9.  Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A.

Authors:  D L Stevens; M H Tanner; J Winship; R Swarts; K M Ries; P M Schlievert; E Kaplan
Journal:  N Engl J Med       Date:  1989-07-06       Impact factor: 91.245

10.  Risk factors for pediatric invasive group A streptococcal disease.

Authors:  Stephanie H Factor; Orin S Levine; Lee H Harrison; Monica M Farley; Allison McGeer; Tami Skoff; Carolyn Wright; Benjamin Schwartz; Anne Schuchat
Journal:  Emerg Infect Dis       Date:  2005-07       Impact factor: 6.883

View more
  11 in total

1.  Epidemiology and emm types of invasive group A streptococcal infections in Finland, 2008-2013.

Authors:  P W Smit; L Lindholm; O Lyytikäinen; J Jalava; A Pätäri-Sampo; J Vuopio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-21       Impact factor: 3.267

Review 2.  Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

Authors:  Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

3.  Genomic Characteristics Behind the Spread of Bacteremic Group A Streptococcus Type emm89 in Finland, 2004-2014.

Authors:  Francesca Latronico; Waleed Nasser; Kai Puhakainen; Jukka Ollgren; Hanne-Leena Hyyryläinen; Stephen B Beres; Outi Lyytikäinen; Jari Jalava; James M Musser; Jaana Vuopio
Journal:  J Infect Dis       Date:  2016-10-05       Impact factor: 5.226

4.  Genome Analysis of Streptococcus pyogenes Associated with Pharyngitis and Skin Infections.

Authors:  Joe Ibrahim; Jonathan A Eisen; Guillaume Jospin; David A Coil; Georges Khazen; Sima Tokajian
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

5.  Genome sequence analysis of emm89 Streptococcus pyogenes strains causing infections in Scotland, 2010-2016.

Authors:  Stephen B Beres; Randall J Olsen; Matthew Ojeda Saavedra; Roisin Ure; Arlene Reynolds; Diane S J Lindsay; Andrew J Smith; James M Musser
Journal:  J Med Microbiol       Date:  2017-11-03       Impact factor: 2.472

6.  Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease.

Authors:  Philip M Giffard; Steven Y C Tong; Deborah C Holt; Anna P Ralph; Bart J Currie
Journal:  PLoS Negl Trop Dis       Date:  2019-07-03

7.  Streptococcus pyogenes strains in Sao Paulo, Brazil: molecular characterization as a basis for StreptInCor coverage capacity analysis.

Authors:  Samar Freschi de Barros; Karine Marafigo De Amicis; Raquel Alencar; Pierre Robert Smeesters; Ariel Trunkel; Edilberto Postól; João Nóbrega Almeida Junior; Flavia Rossi; Antonio Carlos Campos Pignatari; Jorge Kalil; Luiza Guilherme
Journal:  BMC Infect Dis       Date:  2015-08-05       Impact factor: 3.090

8.  Emergence of Streptococcus pyogenes emm102 causing toxic shock syndrome in Southern Taiwan during 2005-2012.

Authors:  Jiun-Nong Lin; Lin-Li Chang; Chung-Hsu Lai; Hsi-Hsun Lin; Yen-Hsu Chen
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

Review 9.  The contribution of group A streptococcal virulence determinants to the pathogenesis of sepsis.

Authors:  Mark Reglinski; Shiranee Sriskandan
Journal:  Virulence       Date:  2013-10-09       Impact factor: 5.882

10.  The innate immune response elicited by Group A Streptococcus is highly variable among clinical isolates and correlates with the emm type.

Authors:  Márcia Dinis; Céline Plainvert; Pavel Kovarik; Magalie Longo; Agnès Fouet; Claire Poyart
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.